Hospitalisation during study period · chronic bronchitis or COPD
Mucolytic probably leads to lower hospitalisation during study period compared with placebo (moderate certainty).
1 finding from 1 review
FEV₁at end of study · chronic bronchitis or COPD
1 finding from 1 review
Adverse effects · chronic bronchitis or COPD
Mucolytic probably leads to lower adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Death during study period · chronic bronchitis or COPD
Mucolytic showed no clear difference in death during study period compared with placebo (moderate certainty).
1 finding from 1 review
Mortality. · adult parapneumonic effusions and empyema
Fibrinolytics showed no clear difference in mortality. compared with placebo (moderate certainty).
1 finding from 1 review
Referral for thoracic surgery (open or thorascopic) · adult parapneumonic effusions and empyema
Alteplase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).
1 finding from 1 review
Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy · adult parapneumonic effusions and empyema
Alteplase showed no clear difference in overall treatment failure, including mortality, thoracic surgery or… compared with urokinase (low certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Alteplase may leads to higher serious adverse events compared with urokinase (low certainty).
1 finding from 1 review
Referral for thoracic surgery (open or thorascopic) · adult parapneumonic effusions and empyema
Fibrinolytics may leads to lower referral for thoracic surgery. compared with placebo (low certainty).
1 finding from 1 review
Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy · adult parapneumonic effusions and empyema
It is very uncertain whether fibrinolytics changes overall treatment failure, including mortality, thoracic surgery or… compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Fibrinolytics showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · adult parapneumonic effusions and empyema
Streptokinase showed no clear difference in mortality compared with urokinase (low certainty).
1 finding from 1 review
Referral for thoracic surgery (open or thorascopic) · adult parapneumonic effusions and empyema
Streptokinase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).
1 finding from 1 review
Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy · adult parapneumonic effusions and empyema
Streptokinase showed no clear difference in overall treatment failure, including mortality, thoracic surgery or… compared with urokinase (low certainty).
1 finding from 1 review
Serious adverse events · adult parapneumonic effusions and empyema
Streptokinase showed no clear difference in serious adverse events compared with urokinase (low certainty).
1 finding from 1 review
All‐cause mortality · adult parapneumonic effusions and empyema
Alteplase showed no clear difference in mortality compared with urokinase (low certainty).
1 finding from 1 review
Machine usage Hours per night · adults with a diagnosis of OSA
1 finding from 1 review
Machine usage assessed by number of participants using machine for 4 or more hours per night ‐ not measured · adults with a diagnosis of sleep apnoea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptoms · adults with a diagnosis of sleep apnoea
1 finding from 1 review
Withdrawals (parallel group trials/first arm cross‐over trials) · adults with a diagnosis of sleep apnoea
Bi‐PAP showed no clear difference in withdrawals (parallel group trials/first arm cross‐over trials) compared with fixed CPAP (low certainty).
1 finding from 1 review